New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
11:22 EDTAMAGAMAG says ferumoxytol met both primary endpoints in two trials
AMAG said in trial IDA-301 the primary efficacy endpoint for U.S. regulators is the proportion of subjects who achieved a 2.0 g/dL increase in hemoglobin at any time from baseline to week 5; the primary efficacy endpoint for European Union regulators is the mean change in hemoglobin from baseline to week 5. In the IDA-301 trial, ferumoxytol achieved both primary efficacy endpoints. In IDA-302 the same primary efficacy endpoints were used and in the IDA-302 trial, ferumoxytol achieved both primary efficacy endpoints. In IDA-301, the overall rate of reported adverse events was higher in the ferumoxytol group than in the placebo group, although no new safety signals, outside of those described in the current Feraheme label, were observed in this study. In the IDA-302 trial, the overall rates of adverse events and related adverse events were comparable in ferumoxytol- and iron sucrose-treated subjects, and included many attributable to comorbid disease. However, the overall rate of SAEs, both related and unrelated as assessed by the investigator, was higher in ferumoxytol-treated subjects.
News For AMAG From The Last 14 Days
Check below for free stories on AMAG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:20 EDTAMAGAMAG Pharmaceuticals raises FY14 revenue view to $93M-$102M, consensus $93.78M
AMAG Pharmaceuticals sees U.S. Feraheme net product sales of $80M-$87M, revised upward from the company's previous estimate of $75M-$85M; revenue from MuGard, ex-U.S. Feraheme product sales, royalties and milestones of $13M-$15M; lowered cost of goods sold guidance to 13%-15% of Feraheme net product sales from the company's previous estimate of 14%-16%; Increased total operating expense guidance to $87M-$92M from the company's previous estimate of $80M-$85M resulting from increased: Research and development expenses of $21M-$23M; Selling, general and administrative expenses of $66M-$69M; increased net loss guidance to $12M-$14M from the company's previous estimate of $10M-$12M. Both estimates include approximately $11M of interest expense from the $200M convertible debt offering in February 2014; lowered ending cash and investments guidance to $388M-$393M from the company's previous estimate of $392M-$397M at December 31.
07:15 EDTAMAGAMAG Pharmaceuticals reports Q2 EPS (7c), consensus (9c)
Reports Q2 revenue $24.8M, consensus $23.35M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use